- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05681650
HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors
Phase I/II Clinical Trial of HER2 Targeted HypoSti.CAR-T Cells in Treating Patients With HER2 Positive Local Advanced or Metastatic Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Currently, chimeric antigen receptor modified T (CAR-T) cell therapy has achieved a series of achievements in hematological malignancies, however, it still has to face plenty of obstacles in more bulky solid tumors, such as absence of tumor specific antigens, complex immunosuppressive tumor microenvironment, and tumor heterogeneity, which may taken together to restrict the efficacy of CAR-T cells in eliminating solid tumors. Previous studies found that intratumoral hypoxic microenvironment facilitated the development and metastasis of tumor cells. Meanwhile, it was difficult for cytotoxic T cells including CAR-T cells to survive and expand in such a hypoxic microenvironment.
In this study, investigators developed a novel hypoxia-stimulated CAR expression system (HypoSti.CAR) that could enable CAR-T cell effectively expand and survive in hypoxic tumor microenvironment,which has been demonstrated in animal models. Based on the preclinical data, investigators will further conduct this clinical trial in order to test the potential of this novel system targeting HER2 antigen in vivo. In dose escalation period, at least 9 eligible patients will be enrolled and receive 5 doses of HypoSti.CAR-HER2 T cell therapy (1 × 10^6 cells/kg, 3 × 10^6 cells/kg, 6 × 10^6 cells/kg,1 × 10^7 cells/kg, 1.5 × 10^7 cells/kg) according to the "3+3" principle. In dose expansion period, additional 10 to 21 patients will be enrolled to receive HypoSti.CAR-HER2 T cell therapy at dose of recommended phase 2 dose (RP2D), which is determined by data from dose escalation period, including occurrence of dose limiting toxicities (DLT), pharmacokinetics/pharmacodynamics, efficacy and other parameters, to furtherly evaluate the safety and efficacy profiles of HypoSti.CAR-HER2 T cell therapy.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Weidong Han, PhD
- Phone Number: +861066937463
- Email: hanwdrsw69@yahoo.com
Study Contact Backup
- Name: Kaichao Feng, MD
- Phone Number: +861066947300
- Email: timothyfkc@126.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, +86100853
- Recruiting
- Kaichao Feng
-
Contact:
- Kaichao Feng, MD
- Phone Number: +861066947300
- Email: timothyfkc@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 1. Age from 18 to 75 years with estimated life expectancy >3 months.
- 2. Histopathological confirmed advanced or metastatic solid tumors failed to at least first-line treatment or initially diagnosed advanced/metastatic solid tumors that have no NCCN guideline recommended standard first-line therapy. HER2 antigen expression percentage ≥ 30%.
- 3. Have at least one measurable target lesion.
- 4. Fresh solid tumor samples or formalin-fixed paraffin embedded tumor archival samples within 6 months are necessary; Fresh tumor samples are preferred. Subjects are willing to accept tumor rebiopsy in the process of this study.
- 5. Previous treatment must be completed for more than 4 weeks prior to the enrollment of this study, and subjects have recovered to <= grade 1 toxicity.
- 6. Have an Eastern Cooperative Oncology Group performance status (ECOG) of 0 or 2 at the time of enrollment.
- 7. Have adequate organ function, which should be confirmed within 2 weeks prior to the first dose of study drugs.
- 8. Previous treatment with anti-PD-1/PD-L1 antibodies are allowed.
- 9. Ability to understand and sign a written informed consent document.
- 10. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, and up to 90 days after the last dose of the drug.
Exclusion Criteria:
- 1. Active, known or suspected autoimmune diseases.
- 2. Known brain metastases or active central nervous system (CNS). Subjects with CNS metastases who were treated with radiotherapy for at least 3 months prior to enrollment, have no central nervous symptoms and are off corticosteroids, are eligible for enrollment, but require a brain MRI screening.
- 3. Subjects are being treated with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment.
- 4. History of severe hypersensitive reactions to other monoclonal antibodies.
- 5. History of allergy or intolerance to study drug components.
- 6. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
- 7. History or concurrent condition of interstitial lung disease of any grade or severely impaired pulmonary function.
- 8. Uncontrolled intercurrent illness, including ongoing or active systemic infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (excluding insignificant sinus bradycardia and sinus tachycardia) or psychiatric illness/social situations and any other illness that would limit compliance with study requirements and jeopardize the safety of the patient.
- 9. History of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
- 10. Pregnant or breast-feeding. Women of childbearing potential must have a pregnancy test performed within 7 days before the enrollment, and a negative result must be documented.
- 11. Previous or concurrent cancer within 3 years prior to treatment start EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)].
- 12. Vaccination within 30 days of study enrollment.
- 13. Active bleeding or known hemorrhagic tendency.
- 14. Subjects with unhealed surgical wounds for more than 30 days.
- 15. Being participating any other trials or withdraw within 4 weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HypoSti.CAR-HER2 T cells
Enrolled participants will be given a preconditioning regimen consisted of albumin-bound paclitaxel, cyclophosphamide and/or fludarabine before the infusion of HypoSti.CAR-HER2 T cells.
Fludarabine will be administered only before the first dose infusion, and will not be administered before the secondary or multiple doses of HypoSti.CAR-HER2 T cell infusion.
|
Administered intravenously at dose of 100-200mg/m2 on day -5
Dose escalation: dose -1 (1×10^6 cells/kg) ,dose 1 (3×10^6 cells/kg) , dose 2 (6×10^6 cells/kg), dose 3 (1×10^7 cells/kg), dose 4 (1.5×10^7 cells/kg).
Dose expansion: RP2D
Administered intravenously at a total dose of 15-30mg/kg on day -3 and day-2
Administered intravenously at dose of 30mg/m2/d on day -3 and day -2 only in the first infusion of HypoSti.CAR-HER2 T cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment related adverse events
Time Frame: Up to 12 months following the infusion of HypoSti.CAR-HER2 T cells
|
Treatment related adverse events are defined as any medical events since the initiation of preconditioning chemotherapy.
Adverse events will be graded by CTCAE V5.0
|
Up to 12 months following the infusion of HypoSti.CAR-HER2 T cells
|
Incidence of dose limiting toxicities (DLTs)
Time Frame: Up to 28 days following the infusion of HypoSti.CAR-HER2 T cells
|
Dose limiting toxicities are defined as HypoSti.CAR-HER2 T cell related adverse events within the first 28 days that meet the following criteria: grade 3 or higher CRS or CRES, grade 3 or higher cutaneous/ mucosal toxicity, and any other grade 4 toxicities.
|
Up to 28 days following the infusion of HypoSti.CAR-HER2 T cells
|
Determination of the maximum tolerated dose (MTD)
Time Frame: Up to 28 days following the infusion of HypoSti.CAR-HER2 T cells
|
Maximum tolerated dose is defined as the highest dose that is less than or equal to 2 DLT among 6 subjects.
|
Up to 28 days following the infusion of HypoSti.CAR-HER2 T cells
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: Up to 3 years
|
Objective response rate is defined as complete response (CR) or partial response (PR) by RECIST 1.1or iRECIST
|
Up to 3 years
|
Time to response (TTR)
Time Frame: Up to 3 years
|
Time to response is defined as the time from HypoSti.CAR-HER2 T cell infusion to first assessed CR or PR by investigators according to RECIST 1.1or iRECIST.
|
Up to 3 years
|
Duration of response (DOR)
Time Frame: Up to 3 years
|
Duration of response is defined as the time from objective response (OR) until documented tumor progression date among responders.
|
Up to 3 years
|
Progression Free Survival (PFS)
Time Frame: Up to 3 years
|
Progression Free Survival is defined as the time from HypoSti.CAR-HER2 T cell infusion to documented disease progression or death.
|
Up to 3 years
|
Overall Survival (OS)
Time Frame: Up to 3 years
|
Overall Survival is defined as the time from HypoSti.CAR-HER2 T cell infusion to the date of death.
|
Up to 3 years
|
Number and copy number of HypoSti.CAR-HER2 T cell
Time Frame: Up to 3 years
|
Number and copy number of HypoSti.CAR-HER2 T cell are assessed by number in peripheral blood and tumor tissue.
|
Up to 3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Jianqing Xu, PhD, Fudan University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Cyclophosphamide
- Paclitaxel
- Albumin-Bound Paclitaxel
- Fludarabine
Other Study ID Numbers
- CHN-PLAGH-BT-076
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HER2 Positive Advanced Solid Tumors
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingHER2-positive Advanced Solid TumorsChina
-
Shanghai Pharmaceuticals Holding Co., LtdRecruitingHER2-positive Advanced Solid TumorsChina
-
Krankenhaus NordwestTerminatedHer2/Neu Positive Advanced Solid TumorsGermany
-
Bliss Biopharmaceutical (Hangzhou) Co., LtdActive, not recruitingLocally Advanced/Metastatic HER2 Positive Solid TumorsChina, United States
-
Bio-Thera SolutionsUnknownHER2-Positive Solid TumorsChina
-
Hangzhou Adcoris Biopharmacy Co., LtdEnrolling by invitationHER2-positive Advanced Solid TumorChina
-
Bristol-Myers SquibbCompletedSolid Tumors That Overexpress HER2 (HER2 Positive)United States, Canada
-
Wuhan YZY Biopharma Co., Ltd.Not yet recruitingHER2-Positive Solid Tumors
-
Peking UniversityRemeGen Co., Ltd.RecruitingHER2-Positive Solid TumorsChina
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdPeking UniversityCompletedHER2-positive Solid TumorsChina
Clinical Trials on Albumin-bound paclitaxel
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast CarcinomaUnited States
-
Anne NoonanNational Cancer Institute (NCI)RecruitingStage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic AdenocarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); Celgene CorporationCompletedRecurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung CancerUnited States
-
China Medical University, ChinaRecruiting
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Cancer Institute and Hospital, Chinese Academy...UnknownUterine Cervical CancerChina
-
Peking UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingGastric Cancer | Adenocarcinoma of Esophagogastric JunctionChina
-
Tang-Du HospitalActive, not recruitingNon-small-cell Lung Cancer (NSCLC)China
-
Tianjin Medical University Cancer Institute and...Recruiting